The 8 most recent market catalysts affecting $MAIA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bullish
Impact 85
MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer
MAIA Biotechnology reported highly positive interim efficacy data from its Phase 2 THIO-101 study for advanced non-small cell lung cancer, demonstrating an 88% disease control rate…
Nov 10, 2026
Corporate Catalyst
Bearish
Impact 55
MAIA Biotechnology Reports Third Quarter 2026 Financial Results
MAIA Biotechnology reported its Q3 2026 financial results, highlighting a reduction in its operating loss and an improvement in diluted EPS loss year-over-year. This indicates some…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 65
MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer
MAIA Biotechnology announced it received regulatory approval from Spanish and Portuguese health authorities to begin screening patients for its Phase 3 THIO-104 clinical trial for …
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
MAIA Biotechnology Says Enrollment In Phase 3 THIO-104 Lung Cancer Trial Of Ateganosine Reaches 65, Targets Over 100 By Year-End
This headline signals positive operational progress for MAIA Biotechnology, as reaching 65 enrollments and targeting over 100 by year-end for a Phase 3 trial is a crucial step in d…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 65
MAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer
MAIA Biotechnology has dosed its first U.S. patient in the Phase 2 THIO-101 trial expansion for ateganosine in third-line NSCLC. This is a positive development as it signifies prog…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
MAIA Biotechnology CEO Vlad Vitoc Buys 73K Shares At An Average Price Of $1.37 Per Share; Board Member Ramiro Guerrero Buys 185,078 Shares At An Average Price Of $1.36 Per Share
MAIA Biotechnology's CEO and a board member collectively purchased over 250,000 shares of company stock, representing a substantial vote of confidence from insiders. This insider b…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 65
MAIA Biotechnology Files $150M Mixed Shelf Offering
MAIA Biotechnology filed a mixed shelf offering, allowing them to issue up to $150 million in various securities like common stock, preferred stock, debt securities, or warrants. T…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
MAIA Biotechnology's Q2 earnings report indicates a loss of $(0.13) per share, which is worse than the analyst consensus of $(0.11). This 18.18% miss is a key negative indicator fo…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.